Wallace DJ, et al. - In this multicenter, open-label, continuation study, intravenous (IV) belimumab plus standard of care (SOC) therapy for systemic lupus erythematosus (SLE) was investigated for its long-term safety and efficacy in patients with active, autoantibody-positive SLE. Patients with SLE who completed a phase II, double-blind study were administered IV belimumab every 4 weeks in conjunction with SOC therapy. In this longest to date study, belimumab treatment in patients with SLE in clinical trials. Belimumab was well tolerated with no new safety concerns, and efficacy was maintained in patients who continued the study. For patients who initially exhibited a satisfactory response to belimumab, the treatment continues to be well tolerated and provides long-term disease control.